# A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

> **NCT05150691** · PHASE1,PHASE2 · RECRUITING · sponsor: **DualityBio Inc.** · enrollment: 796 (estimated)

## Conditions studied

- HER2-positive Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** DB-1303/BNT323
- **DRUG:** Pertuzumab Injection
- **DRUG:** Ritonavir
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT05150691
- **Lead sponsor:** DualityBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-31
- **Primary completion:** 2026-04
- **Final completion:** 2027-10
- **Target enrollment:** 796 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05150691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05150691, "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05150691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*